April 13th 2022
Results of the phase 2 AURELIO-03 trial show SOT101 plus PD-1 inhibition induced responses in patients with advanced solid tumors.
VERSATILE-002 Trial to Enroll Previously Treated HPV+ HNSCC Per Protocol Amendment
June 3rd 2021A new treatment arm of a phase 2 trial examining PDS0101 plus pembrolizumab in patients with HPV-related head and neck cancers will be opened to patients with immune checkpoint inhibitor–pretreated disease.
Tislelizumab Improves OS Compared With Chemo in Advanced Unresectable or Metastatic ESCC
January 28th 2021The phase 3 RATIONALE 302 trial demonstrated that compared to chemotherapy, tislelizumab showed a statistically significant and clinically meaningful improvement in overall survival in the intention-to-treat population of patients with advanced or metastatic esophageal squamous cell carcinoma.
Strategies Proposed to Improve Management of Immune-Related Adverse Events
January 11th 2021Though the majority of immune-related adverse events (irAEs) can be managed with corticosteroids and other immunosuppressive treatments, life-threatening and sometimes fatal events have still been reported thus revealing a need to develop measures for effective management.
Ongoing Phase 1/2 Trial of FLX475 Shows Promising Activity in Multiple Cancer Indications
November 17th 2020The results demonstrated preliminary evidence of monotherapy activity, encouraging efficacy in combination with the PD-1 checkpoint inhibitor pembrolizumab (Keytruda), and biomarker data supporting FLX475’s mechanism of action.
Higher Serum PD-L1 Level Predicts Increased OS With Lapatinib vs Trastuzumab in CCTG MA.31 Study
October 18th 2020The researchers hypothesized “that serum PD-L1 may identify a subgroup of patients with HER2-positive [metastatic breast cancer] who may benefit the most from the addition of novel immunotherapies to trastuzumab.”
6-Month PFS for 12-Month OS Model Appears Effective for Estimating 12-Month OS
October 7th 2020Researchers suggested these findings may assist in better selection and prioritization of immune checkpoint inhibitor agents for testing in randomized clinical trials based on phase 2 single arm randomized clinical trial results.
Adding Immunotherapy to Radiotherapy May Improve OS in Patients with Brain Metastases
October 3rd 2020This study found that the addition of immunotherapy to radiotherapy was associated with improved overall survival compared with radiotherapy alone in patients with brain metastases who received definitive surgery of the primary tumor site.
FDA Clears Phase 1 Clinical Trial of ATA2271 for Treatment of Advanced Mesothelioma
September 15th 2020The FDA accepted an investigational new drug application providing clearance to begin an open-label, single-arm phase 1 clinical trial of ATA2271, a next-generation mesothelin targeting CAR T-cell therapy.
ICIs May be Used as Individualized Therapy in Select Solid Organ Transplant Recipients
August 31st 2020Though further research is necessary, researchers suggested that immune checkpoint inhibitors can be used as an individualized therapy in certain patients who have undergone solid organ transplantation.
Study Shows Nivolumab-Chemo Combination Improves Survival in Gastric and Esophageal Cancers
August 11th 2020Bristol Myers Squibb announced that their phase 3 CheckMate-649 trial demonstrated superior overall survival and profession-free survival using nivolumab plus chemotherapy to treat patients with gastric and esophageal cancers.
Personalized Cancer Vaccine with Atezolizumab Shows Promise in Advanced Solid Tumors
June 22nd 2020RO7198457 in combination with atezolizumab induced significant levels of neoantigen-specific immune responses with a manageable safety profile in patients with locally advanced or metastatic solid tumors.
Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen
April 29th 2020Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.